Reata Announces Positive Interim Data on LARIAT Phase 2 Clinical Trial for PAH
News, Pulmonary Hypertension
Reata Pharmaceuticals released interim data from its extension Phase 2 LARIAT clinical trial evaluating bardoxolone methyl for the treatment of pulmonary arterial hypertension (PAH). Bardoxolone methyl is an investigational, oral, once-daily antioxidant inflammation modulator ... Read more